(Total Views: 314)
Posted On: 09/19/2018 5:36:40 PM
Post# of 72446
I was curious about Celgene and decided to look on their website...as someone point out, the title in the about tab is "a Global Biopharmaceutical company"...which is curiously similar to the 10K reference. Beyond that I noticed a psoriasis page and the following question/excerpt was noted...
How can clinical trials evolve to more comprehensively measure meaningful improvements for patients with plaque psoriasis?
“It’s becoming fairly common to have secondary endpoints that include itching and quality of life, which is progress. We’re seeing better management of psoriasis sub-types, such as patients with severe hand and foot psoriasis or patients who have severe arthritis without a lot of skin disease. Since the condition is quite diverse, there’s no one treatment for every patient. So the more safe and effective treatment options we have, the better for patients with plaque psoriasis.
Did the survey questions that IPIX included get at the first sentence?
How can clinical trials evolve to more comprehensively measure meaningful improvements for patients with plaque psoriasis?
“It’s becoming fairly common to have secondary endpoints that include itching and quality of life, which is progress. We’re seeing better management of psoriasis sub-types, such as patients with severe hand and foot psoriasis or patients who have severe arthritis without a lot of skin disease. Since the condition is quite diverse, there’s no one treatment for every patient. So the more safe and effective treatment options we have, the better for patients with plaque psoriasis.
Did the survey questions that IPIX included get at the first sentence?
(3)
(0)
